Auto-Injectors Market Forecasts to 2030 - Global Analysis By Type, Route of Administration, Therapy, Type of Molecule, Distribution Channel, End User and By Geography

According to Stratistics MRC, the Global Auto-Injectors Market is accounted for $2.03 billion in 2023 and is expected to reach $7.94 billion by 2030 growing at a CAGR of 21.5% during the forecast period. An auto-injector is a syringe with a needle that has been pre-charged with a dosage of drugs and is spring-charged. When a sliding motion is used to press the device into the body, the system activates and delivers a precise dosage of a medication. The self-administration of epinephrine by migraineurs or for medical and emergency treatments is frequently done with the aid of auto-injectors.

According to the National Health Interview Survey (NHIS), nearly 52% of the adult population in the US is diagnosed with at least one chronic condition, such as asthma, diabetes, and hypertension.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The demand for auto-injectors has also increased as chronic diseases like diabetes, rheumatoid arthritis, and multiple sclerosis are becoming more common. Auto-injectors provide a secure and reliable way to administer these medications, which are frequently injected regularly to treat these conditions. For instance, The International Diabetes Federation (IDF) estimates that 537 million people worldwide had diabetes in 2021, and that number is expected to rise sharply in the years to come. Since the majority live in low- and middle-income countries, diabetes directly causes 1.5 million deaths annually. Moreover, market statistics for auto-injectors will increase due to the rising significance of preventive care in both developed and developing economies.

Restraint:

Availability of alternative modes of drug delivery

Traditionally, injectable medications have been delivered with a syringe and are painful to receive. This is why other administration methods like oral, nasal, and topical routes are gaining more attention from both patients and healthcare professionals. Additionally, owing to technological developments, needle-free injectors have been created, and a lot of drugs are administered frequently for conditions like growth hormone deficiency, rheumatoid arthritis, and diabetes, among others. As a result, patients with these conditions may develop needle phobia as a result of repeated injections, which would encourage them to switch to alternative drug delivery methods.

Opportunity:

Rising shift of therapy to home settings

Home care settings are receiving more attention worldwide. This is supported by improvements in medical technology, significant financial savings over hospital-based treatments, and changing patient preferences. Additionally, the development of auto-injectors with technological advancements like audio-visual cues for easy handling and administration, connectivity for better assistance, and large dose and volume devices for less frequent drug administration are all supporting the adoption of auto-injectors in home care settings, which consequently offers opportunities in the market.

Threat:

Regulatory challenges

Stringent regulatory requirements, especially in the healthcare and pharmaceutical sectors, can pose significant challenges. Changes in regulations, compliance issues, and lengthy approval processes can delay product launches. As a result, it increases costs, which might impede market entry and growth.

COVID-19 Impact:

The COVID-19 outbreak has interfered with a number of healthcare operations, but the auto-injector market is still experiencing strong revenue growth. An additional driver of market demand is the rising incidence rate of various respiratory complications among COVID-19 patients. Auto-injectors are self-administration drug devices that contain a range of medications for the treatment of various illnesses, including rheumatoid arthritis, diabetes, and others. Additionally, auto-injectors aid in the administration of a regular dose of medication, which became very popular during the COVID-19 pandemic when healthcare facilities were overrun with COVID patients.

The rheumatoid arthritis segment is expected to be the largest during the forecast period

Over the forecast period, rheumatoid arthritis is anticipated to hold a sizable market share. An autoimmune condition called rheumatoid arthritis (RA) occurs when the body's immune system attacks the joints, inflaming the synovium and resulting in swelling and pain in the joints and the surrounding tissues. Women are more likely to have arthritis than men, and it primarily affects the elderly. For instance, According to the United Nations World Population Prospects 2020 report, there are currently 727 million people in the world who are 65 or older, and by the year 2050, this number is projected to more than double. As the prevalence of arthritis among the elderly population rises, this market segment will expand over the forecast period.

The homecare settings segment is expected to have the highest CAGR during the forecast period

During the anticipated timeframe, the segment for homecare settings is predicted to have the highest CAGR. The use of auto-injectors is anticipated to rise in response to the rising demand for healthcare services provided at home. Numerous medications, including DMARDs, biologics, and vaccines, can be administered using these devices. Moreover, the demand for auto-injectors in homecare settings will therefore be driven by the growing sophistication of healthcare infrastructure and accessibility, which is assisting in the market's expansion.

Region with largest share:

Throughout the forecast period, North America is anticipated to account for the largest market share for disposable auto-injectors. The market in the region is boosted by factors like early adoption of technologically advanced products and product approvals, as well as an increase in the prevalence of chronic diseases. In addition, the United States market is growing as a result of rising technological advancements, increased entry of new players, and quick adoption of advanced products. The North American region is therefore anticipated to experience growth as a result of the aforementioned factors.

Region with highest CAGR:

Due to factors like the rising prevalence of diabetes and anaphylaxis brought on by food allergies in nations like India, China, Japan, Singapore, and Australia, Asia Pacific is predicted to grow at the highest CAGR. In numerous Asian nations, diabetes is a major health concern. As a result, the use of insulin auto-injectors has increased to assist people with diabetes in effectively managing their condition. Due to the aforementioned factors, the Asia-Pacific region offers significant potential for growth in the auto-injector market.

Key players in the market:

Some of the key players in Auto-Injectors Market include: AbbVie Inc, Amgen Inc., Antares Pharma, Bayer AG, Becton, Dickinson and Company, Biogen, Eli Lilly and Company, F. Hoffmann La Roche Ltd., GlaxoSmithKline plc, Halozyme Therapeutics Inc., Johnson & Johnson, medmix Ltd., Merck KGaA, Owen Mumford Ltd., Pfizer Inc., Recipharm AB, Teva Pharmaceutical and Ypsomed.

Key Developments:

In October 2023, AbbVie announced that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson's Disease (PD). Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction that is believed to be a major contributing factor to Parkinson's disease pathogenesis and progression.

In October 2023, Amgen announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.

Types Covered:

• Disposable
• Reusable

Route of Administration Covered:

• Subcutaneous
• Intramuscular

Therapies Covered:

• Anaphylaxis
• Asthma
• Diabetes
• Hormone Therapy
• Migraine
• Multiple Sclerosis
• Oncology
• Rheumatoid Arthritis
• Other Therapies

Type of Molecules Covered:

• Monoclonal Antibody
• Peptide
• Protein
• Small Molecule

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

End Users Covered:

• Home Care Settings
• Hospitals & Clinics
• Ambulatory Care Settings

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances